Biocon Share Price
28 Oct, 2026 3:58 PM (IST)
Biocon Performance
- Today's Low
- ₹331
- Today's High
- ₹351
- 52 Week Low
- ₹318
- 52 Week High
- ₹447
- Open Price₹331
- Previous Close₹332
- Volume4,402,298
- 50 DMA₹372.20
- 100 DMA₹386.00
- 200 DMA₹388.00
Biocon Chart
Investment Returns
- Over 1 Month -8.23%
- Over 3 Month -19.61%
- Over 6 Month -3.12%
- Over 1 Year -2.7%
Smart Investing Starts Here Start SIP with Biocon for Steady Growth!
Biocon Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 115.4
- PEG Ratio
- 4
- Market Cap Cr
- 57,153
- P/B Ratio
- 1.7
- Average True Range
- 9.5
- EPS
- 3
- Dividend Yield
- 0.1
- MACD Signal
- -13.3
- RSI
- 45.93
- MFI
- 47.42
Latest Stock News Updates
Earnings Conference Call for Analysts and Investors
- BSE India
- 2 days ago
Biocon Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve To approve and take on record the un-audited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30, 2026
- BSE India
- 2 days ago
The biosimilar to Johnson & Johnson's Stelara will be commercialised in nine additional markets, expanding Biocon's global reach in immunology
- Business Standard
- 2 days 11 hours ago
Biocon Financials
Biocon Technicals
EMA & SMA
- Bearish Moving Average 9
- Bullish Moving Average 7
- 20 Day
- ₹350.10
- 50 Day
- ₹372.20
- 100 Day
- ₹386.00
- 200 Day
- ₹388.00
Resistance and Support
- R3 377.50
- R2 364.10
- R1 357.40
- S1 337.30
- S2 323.90
- S3 317.20
Biocon Corporate Actions - Bonus, Splits, Dividends
Biocon F&O
About Biocon
Biocon limited is a biopharmaceutical company in India and it is Asia's largest biotechnology company. The company was founded by Kiran Mazumdar-Shaw in 1978 and is headquartered in Bengaluru, India. The company has more than 16,545 employees as on March 2023. It focuses on all phases of the product cycle from researching to development and then introducing them to the market. They mainly concentrate on the research and development of advanced therapies for the treatment of cancer, diabetes, and autoimmune disease. The company's medicines are helping the lives of patients in more than 120 countries by providing access to all their medicines and therapies.
Some of Biocon's important brands in India are INSUGEN (rh-insulin), BIOMAb EGFR (Nimotuzumab), CANMAb (Trastuzumab),KRABEVA (Bevacizumab), ALZUMAb(Itolizumab), BLISTO (Glimepiride + Metformin), BASALOG (Glargine) & so on.
View More- NSE Symbol
- BIOCON
- BSE Symbol
- 532523
- Managing Director,Chief Executive Officer
- Mr. Shreehas Tambe
- ISIN
- INE376G01013
Similar Stocks to Biocon
Popular Stocks
Biocon FAQs
Biocon share price is ₹350 As on 28 October, 2026 | 20:55
The Market Cap of Biocon is ₹57153.4 Cr As on 28 October, 2026 | 20:55
The P/E ratio of Biocon is 115.4 As on 28 October, 2026 | 20:55
The PB ratio of Biocon is 1.7 As on 28 October, 2026 | 20:55
The 52 week High & Low of Biocon is ₹447.2/₹318.4 respectively As on 28 October, 2026 | 20:55
Biocon has an operating revenue of Rs.7,290.70 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 16% is great. However, analysts are of mixed views on the stock.
Biocon Ltd. has declared 17 dividends since July 1, 2004.
The stock price CAGR of Biocon Limited for 10 Years is 24%, 5 Years is 17%, 3 Years is 5%, 1 Year is -21%.
The debt-to-equity ratio of Biocon Limited is 39% which signals a healthy balance sheet.
The ROE of Biocon Limited is 9% which is fair but needs improvement.
Mr. Siddharth Mittal is the Managing Director and CEO of Biocon Limited.
The company's shares can be bought online by opening a demat account with 5paisa in either web or app.
According to the record analysis of moneyworks4me, Biocom limited is an average quality company.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.